Compare AngloGold Ashanti Limited (AU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Neurocrine Biosciences Inc — how do they compare? AngloGold Ashanti Limited trades at $98 (market cap $49.19B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: AngloGold Ashanti Limited is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AU | NBIX | |
|---|---|---|
Market Cap | $49.19B | $16.76B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $185.50 |
52-Week Low | $52.15 | $123.10 |
Enterprise Value | $48.20B | $16.78B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
